{"entity":{"id":"nct06117566","kind":"trial","name":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.","summary":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06117566 by Shanghai Jiatan Pharmatech Co., Ltd, with 100 participants planned, started 2022-11-18 and due to reach its primary completion in 2025-11-09. Interventions recorded: WX390 and Toripalimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06117566","url":"https://clinicaltrials.gov/study/NCT06117566"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06117566","phase":"1/2","setting":"A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","enrolled":100,"outcomes":[]},"route":"/trials/nct06117566/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}]}}